Browsing Tag
Cipla USA
3 posts
Why is Cipla’s InvaGen cutting 205 New York jobs while the US pipeline keeps expanding?
InvaGen Pharmaceuticals is preparing 205 permanent layoffs across two New York facilities effective November 27, adding a workforce dimension to Cipla's North American reset after regional revenue fell 21% in its latest reported quarter. The notices cite economic reasons but do not indicate a complete withdrawal from US manufacturing.
Cipla Limited (NSE: CIPLA) secures FDA approval for generic nintedanib capsules, entering a $3.8bn U.S. pulmonary fibrosis market
Cipla wins FDA approval for generic nintedanib capsules for IPF, targeting Boehringer Ingelheim's $3.76B Ofev market. Here's what the launch means for investors. Read more.
Cipla and Orbicular bring first generic liraglutide for obesity to U.S. market, targeting $127m opportunity
Cipla launches generic Saxenda (liraglutide) in the U.S. via partner Orbicular's FDA approval. What this means for GLP-1 generics competition, payers, and Cipla's peptide strategy. Read more.